PROCEPT BioRobotics Announces Closing of Upsized IPO

 PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the closing of its upsized initial public offering of 7,539,400 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 983,400 additional shares of common stock, at a public offering price of $25.00 per share. All of the shares were offered by PROCEPT. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $188.5 million. The shares began trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol "PRCT."

BofA Securities and Goldman Sachs & Co. LLC acted as joint lead bookrunning managers for the offering. Cowen, Guggenheim Securities and SVB Leerink acted as co-managers.

https://www.bakersfield.com/ap/news/procept-biorobotics-corporation-announces-closing-of-upsized-initial-public-offering-and-full/article_d1703e0a-be24-55c6-bf75-129c0fdd044a.html